Summit Therapeutics reports a survival benefit for its cancer drug in a trial. Survival is the endpoint that matters most in oncology, so this is the line the tape will trade around. $SMMT
Summit Therapeutics reports survival benefit for cancer drug in trial.
SMMT
$14.15
-6.14%
What changed
Summit Therapeutics reports survival benefit for cancer drug in trial.
Why it matters
Summit Therapeutics reports survival benefit for cancer drug in trial. — impact context not separately stored; see What changed.